Metastatic Colorectal Cancer: Prevention, Control and Methods of Adverse Events Correction in the Case of Regorafenib Therapy
Multikinase inhibitor regorafenib significantly improves progression-free survival and overall survival in the case of the ineffectiveness of anticancer therapy based on oxaliplatinum and irinotecan, as well as targeted therapy in patients with metastatic colorectal cancer. However, the maximum effect of therapy can be achieved only by taking into account the profile of undesirable phenomena appearing in the case of using of regorafenib, ensuring their timely diagnosis and successful prevention. Often, the duration of treatment with regorafenib is determined not so much by its effectiveness in relation to the tumor process, but by the skill and competency of the doctor to stop side timely rationally as well as to maintain an adequate dosing regimen.